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1  | GLYCOSPHINGOLIPIDS A S 
FUNC TIONAL MOLECULES ON THE CELL 
SURFACE
Cancer- associated glycosphingolipids have been considered as 
tumor markers,1 and used as diagnostic markers and targets of can-
cer treatment.2 There have been a number of reports on the spe-
cific expression of various glycosphingolipids in individual cancers. 
These include ganglioside GD3 in melanomas3 and T- cell lympho-
blastic leukemia,4,5 GD2 in neuroblastomas,6 osteosarcomas,7,8 small 
cell lung cancers9,10 and breast cancers,11 and globotriaosylceramide 
in Burkitt's lymphomas.12 Sialyl Lewis A has also been used as a 
tumor marker of pancreatic, gastrointestinal,13 and other epithelial 
cancers;14 this structure is carried on both glycosphingolipids and 
mucins.2
Remodeling of carbohydrate structures on proteins and lipids by 
artificial manipulation of glycosyltransferase genes has enabled us to 
further analyze the roles of these cancer- associated glycosphingo-
lipids in cancer cells in addition to mere cancer markers.15 Generally 
speaking, disialyl glycosphingolipids confer malignant properties in 
various cancer systems. In particular, tandem- repeated sialic acid- 
structures such as those in GD3 and GD2 enhanced the malignant 
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Cancer- associated glycosphingolipids have been used as markers for diagnosis and 
targets for immunotherapy of malignant tumors. Recent progress in the analysis of 
their implications in the malignant properties of cancer cells revealed that cancer- 
associated glycosphingolipids are not only tumor markers, but also functional mole-
cules regulating various signals introduced by membrane microdomains, lipid rafts. In 
particular, a novel approach, enzyme- mediated activation of radical sources com-
bined with mass spectrometry, has enabled us to clarify the mechanisms by which 
cancer- associated glycosphingolipids regulate cell signals based on the interaction 
with membrane molecules and formation of molecular complexes on the cell surface. 
Novel findings obtained from these approaches are now providing us with insights 
into the development of new anticancer therapies targeting membrane molecular 
complexes consisting of cancer- associated glycolipids and their associated membrane 
molecules. Thus, a new era of cancer- associated glycosphingolipids has now begun.
K E Y W O R D S
cancer marker, cancer-associated antigen, cluster, enzyme-mediated activation of radical 
sources, ganglioside, glycosphingolipid, lipid raft
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properties of cancer cells, such as cell proliferation, cell invasion and 
migration, cell adhesion, and metastasis.15-17 In contrast, monosialyl 
gangliosides, such as GM1, GM3, and GM2 often suppress malignant 
properties of various cancer cells.18-20 Therefore, GD3 synthase is a 
key enzyme determining cell phenotypes based on the expression 
patterns of gangliosides, as shown in Figure 1.
2  | ENIGMA IN THE AC TION 
MECHANISMS FOR GLYCOSPHINGOLIPIDS 
HA S BEEN GET TING DISCLOSED
How these glycosphingolipids affect the phenotypes and behaviors 
of cells in various manners has also been rigorously analyzed, and 
molecular mechanisms by which glycosphingolipids modify cell sign-
aling based on the interaction with other molecules existing on the 
same membrane (cis- binding) or on the different cell surface (trans- 
binding) have been reported.21 Although soluble and/or cell surface 
ligand molecules that gain access from outside cells are important 
as trans- interacting molecules with glycosphingolipids,22 knowledge 
on cis- interaction on the cell surface has recently advanced. In this 
group, growth factor receptors and adhesion receptors such as the 
integrin family are mainly defined as cis- interacting molecules with 
glycosphingolipids on the cell surface, leading to the modification of 
cell signals mediated by those receptors16,17(Figure 2). In Figure 2A, 
a representative example of signal convergence in melanomas is 
presented. Activation signals mediated by growth factor recep-
tors are merged with adhesion signals by integrins, resulting in the 
convergence of signals, leading to the markedly enhanced promotion 
of downstream molecules such as AKT, p130Cas, and paxillin, and 
increased malignant properties of melanoma cells.16,17
Results on increased adhesion signals by the integrin- FAK axis 
are presented in Figure 2B.
The recent development of a new approach to define interact-
ing molecules with cancer- associated glycosphingolipids on the 
surface of living cells has markedly promoted understanding of 
these interactions, namely EMARS/MS, developed by Honke and 
Kotani.23 To analyze molecular clustering on the cell surface, co- 
immunoprecipitation has been used. Cross- linking analysis, includ-
ing photoaffinity labeling, with the aid of chemical cross- linkers has 
also been used, leading to partly successful results with a restricted 
range of clustered molecules. Morphological visualization with fluo-
rescence microscopy or electron microscopy has been used to obtain 
useful findings. However, all target molecules of these approaches 
need to be known at the starting points. Compared with these cur-
rent methods, EMARS is a very powerful approach. The advantages 
of this approach can be summarized as follows: (a) using living cells 
to analyze events on the cell surface, corresponding to the size of 
microdomains; (b) no need for special equipment, and easy to carry 
out; and (c) applicable for comprehensive analysis of clustering mole-
cules with particular targets, enabling the identification of molecular 
profiles including those of unknown molecules.24
Using “cancer- specific” mAbs, we have identified candidate 
molecules that might physically and functionally interact with 
cancer- associated glycosphingolipids on the cell surface within ca. 
300 nm, as shown in Figure 3.23,24 Thus, how glycosphingolipids are 
F IGURE  1 Synthetic pathway of major acidic glycolipids and differential roles of gangliosides in cancers. Disialyl gangliosides (GD3, 
GD2) and monosialyl gangliosides (GM3, GM2, GM1) exert opposite effects to regulate cancer properties, ie, tumor- enhancing function and 
tumor- suppressing function, respectively. GD3 synthase (ST8SIA1) is a key enzyme determining the main direction of ganglioside synthesis. 
Cer, ceramide
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expressed on the outer layer of the cell membrane and exert their 
roles in the regulation of cell phenotypes is now being clarified.
Consequently, EMARS/MS could be a very powerful approach 
to identify cooperating molecules with cancer- associated gly-
cosphingolipids. The features of molecular assembly depending 
on the changes in cell states can also be defined. Furthermore, 
we can investigate the roles of molecular complexes consisting 
of cancer- associated glycosphingolipids and EMARS- defined 
molecules. Downstream molecules activated by these molecular 
complexes have also been reported, as described in the following 
section.
3  | C ANCER- A SSOCIATED 
GLYCOSPHINGOLIPIDS PL AY ROLES 
THROUGH COMPLE X FORMATION WITH 
MEMBR ANE MOLECULES
As described above, ganglioside GD3 has been considered as a 
melanoma- specific glycolipid antigen,25 and been used as a tar-
get of Ab therapy and/or immune cell- mediated therapy for ma-
lignant melanomas.26,27 Roles of GD3 in melanomas have been 
reported based on experiments using cells transfected with GD3 
synthase cDNA, showing its effects on the activation of sign-
aling molecules located downstream of growth factor recep-
tors28 or adhesion receptors, integrins.17 An EMARS/MS analysis 
(Figure 3) with melanoma cells using anti- GD3 mAb revealed vari-
ous membrane molecules as candidate molecules that associate 
with GD3.29 Among them, Neogenin- 1 was defined as a GD3- 
associating molecule and also as a GEM/raft- residing molecule 
exclusively in GD3+ cells.30 Neogenin- 1 was shown to be involved 
in enhancement of the malignant properties of melanomas such 
as increased cell growth, invasion, and migration, indicating that 
Neogenin- 1 might be an effector molecule exerting the effects of 
melanoma- specific ganglioside, GD3 (Figure 4A). Consequently, 
GD3 expression resulted in the shift of Neogenin- 1 (Figure 4B) 
but also of γ- secretase to lipid rafts from the nonraft compart-
ment, leading to increased cleavage of the intracytoplasmic 
domain of Neogenin- 1. Neogenin intracytoplasmic domain pro-
moted expression of multiple genes such as GPR126, STXBP5, 
MMP16, SPATA31A1, and S6K, as identified by ChIP- sequencing, 
possibly playing central roles in enhancing the malignant proper-
ties of melanomas30 (Figure 4A).
Using a replication- competent avian leukemia virus splice accep-
tor system,31 we analyzed murine gliomas with a focus on the expres-
sion of gangliosides on the cell surface.32 Astrocytes transfected with 
F IGURE  2 Regulation of cell signals at lipid rafts by cancer- associated glycolipids. A, Two main signaling pathways modulated by 
glycosphingolipids converge to enhance malignant properties of cancer cells. An example of ganglioside GD3 expressed in melanoma cells 
is shown. Cis- acting vs trans- acting molecules with glycosphingolipids on the cell membrane are also shown as well as 2 signaling pathways. 
B, An example of GD3- mediated enhancement of adhesion signals in melanoma cells. Increased cell adhesion of GD3+ cells compared with 
GD3− cells as measured by real- time cell electronic sensing (left). Increased phosphorylation levels of FAK during cell adhesion to collagen 
type I (right). Modified from Ohkawa et al17 with permission. HGF, hepatocyte growth factor
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PDGFB showed some levels of GD3 expression, and GD3+ and GD3– 
astrocytes were separated, enabling us to analyze the effects of GD3/
GD2 expression on astrocytes. Thus, it was shown that GD3/GD2 ex-
pression increased cell growth, invasion, and migration. To clarify the 
mechanisms by which GD3/GD2 enhance the malignant properties of 
gliomas, EMARS/MS was carried out, and PDGFRα was defined as a 
GD3- associating molecule in murine gliomas.32 Only GD3 formed a 
molecular complex with PDGFRα, and the Src family Yes was also in-
cluded in the complex, leading to the formation of a ternary molecular 
complex adjacent to the cell membrane.32 This complex activated pax-
illin,32 resulting in the increased invasiveness that is the most notable 
feature of gliomas33 (Figure 5A).
Application of the EMARS/MS approach resulted in the detec-
tion of GD3- associating molecules in human melanoma and murine 
glioma cells, both of which are membrane receptors that regulate 
cell growth/differentiation. In contrast, a similar approach led to the 
detection of an amino acid transporter in SCLC.
Among human lung cancers, SCLC show high frequencies of 
metastasis and recurrence. Therefore, novel Ab therapy targeting 
SCLC- specific antigens has been long expected.34 As a result of 
EMARS/MS using anti- GD2 mAb and GD2 synthase- transfectants 
of SK- LC- 17,9 approximately 20 molecules were identified as can-
didates of GD2- associating molecules.35 These molecules con-
sisted of CD109, uPAR, EphA2, and CD44. Among them, ASCT2, 
a glutamine transporter, was most clearly localized in lipid rafts 
of GD2+ cells. Then we examined roles of ASCT2 in SCLC cells. 
The expression of ASCT2 in SCLC cells resulted in increased pro-
liferation and invasion. ASCT2 colocalized with GD2 in GEM/rafts, 
and they were associated with each other, as shown by multiple 
approaches such as co- immunoprecipitation and the proximity li-
gation assay.35 Consequently, ASCT2 co- operated with GD2 and 
increased the uptake of glutamine, and increased activation levels 
of downstream molecules of mTOR1, such as p- p70 S6K1 and p- 
S635 (Figure 5B).
F IGURE  3 Enzyme- mediated activation of radical sources/mass spectrometry (EMARS/MS). A, Procedures of EMARS/MS analysis for 
identification of glycolipid- associated molecules on the cell surface of living cells are shown (modified from Kotani et al23 with permission). 
Antibodies specific for particular glycolipids are labeled with HRP directly or indirectly (secondary Ab), and then biotin- conjugated aryl azide 
is added, resulting in the biotin labeling of membrane molecules present around target glycolipids (within 200–300 nm). These molecules 
are applied to MS to identify the proteins and aid functional analysis, such as interaction and cooperation with glycolipid antigens. B, An 
representative EMARS reaction is shown, in which the reaction was carried out using anti- ganglioside GD2 mAb for small- cell lung cancer 
(SCLC) cells. Labeled proteins were immunoprecipitated and applied for immunoblotting. Only the sample labeled with the anti- GD2 mAb 
showed multiple bands.35 These proteins were applied to MS
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F IGURE  4 Neogenin was defined 
as a ganglioside GD3- associating 
molecule in melanoma cells by enzyme- 
mediated activation of radical sources/
mass spectrometry. A, Under GD3 
expression, Neogenin colocalized with 
GD3 and γ- secretase in lipid rafts, 
resulting in increased generation of 
Neogenin intracytoplasmic domain 
(NeICD). Eventually, NeICD promotes the 
expression of various genes and enhances 
function of GD3 (modified from Kaneko et 
al30 with permission). B, Floating pattern 
(intracellular localization) of Neogenin 
was analyzed by sucrose density gradient 
ultracentrifugation of Triton X- 100 
extracts from GD3+ (G5) and GD3− (V9) 
melanoma sublines. A shift of Neogenin 
to glycolipid- enriched microdomain 
(GEM)/rafts was clearly indicated by 
immunoblotting (ref. 30)
F IGURE  5 Action of ganglioside- associating molecules defined by enzyme- mediated activation of radical sources/mass spectrometry 
(EMARS/MS) analysis in murine gliomas and human small- cell lung cancer (SCLC) cells. A, Platelet- derived growth factor receptor- α 
(PDGFRα) was defined as a GD3- associating molecule in murine gliomas by the EMARS/MS approach. Specific association of GD3 with 
PDGFRα was identified by co- immunoprecipitation, and activated Yes was also found in the immune complex. Subsequently, it was shown 
that membrane molecular complexes consisting of GD3, PDGFRα and Yes promote glioma invasiveness by activating paxillin.32 B, By 
EMARS/MS, a glutamine transporter, ASCT2, was defined as a GD2- associating molecule in SCLC. ASCT2 cooperates with GD2, resulting 
in the increased activation levels of mTOR1 downstream molecules such as p70S6K1 and S6 in SCLC cells.35 These signals finally induce 
increased cell growth and migration
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4  | GLYCOSPHINGOLIPIDS REGUL ATE 
ARCHITEC TURE AND FUNC TION OF GEM/
R AF TS
The majority of the cancer- associated glycosphingolipids mentioned 
above are considered to localize in GEM/rafts. Indeed, many of the 
EMARS/MS- defined molecules targeting glycosphingolipids were 
detected in GEM/rafts.29,36 Among GEM/raft- residing molecules, 
such as cholesterol, sphingomyelin, GPI- anchored proteins, and gly-
cosphingolipids, the latter 2 are unique as they make up relatively 
uniform lipids and polymorphic nonlipid portions.36 The polymorphic 
portions, ie, proteins or carbohydrates, are exposed to the outside of 
the cell surface, interacting with outward ligands. Glycosphingolipids 
are particularly unique because they interact with outward ligands, 
but also with cis- residing molecules on the same cell membrane, 
playing roles by forming molecular complexes consisting of assem-
bled glycolipids and membrane molecules.
From our experience, alteration of the glycosphingolipid com-
position in cells and tissues resulted in marked changes in the ar-
chitecture and function of GEM/rafts in cultured cells,17,30 and also 
in experimental animals.37 Neo- expression of GD3 induced marked 
changes in the intracellular localization of integrins, Src- family ki-
nases, and Neogenin in melanoma cells. A lack of gangliosides ex-
cept GM3 resulted in the dispersion of GPI- anchored proteins, such 
as complement regulatory proteins, as well as raft marker proteins 
from GEM/rafts in mouse brain tissues.37 Thus, expression patterns 
of glycosphingolipids determine the features of GEM/rafts, ie, pro-
files of GEM/rafts and properties of GEM/rafts as a platform for 
signal regulation. Lipid rafts have been considered to take part in 
the complex protein- protein interactions for the generation of signal 
transduction.38 Lipid rafts can change size (from nanoscale to raft 
“phase”) and composition responding to intra- or extracellular stim-
uli, as shown in Figure 6.39 Therefore, how altered carbohydrates in 
cancer cells regulate the composition and function of GEM/rafts and 
cell signals, and whether individual cancer- associated glycosphin-
golipids form distinct molecular clusters and exert unique signaling, 
remain to be clarified in the future.
5  | DE VELOPMENT OF NOVEL 
TECHNOLOGY ENABLES US TO FURTHER 
UNDERSTAND GLYCOSPHINGOLIPIDS
In addition to the EMARS/MS approach, development of novel 
technologies has brought about a new era of cancer- associated 
glycosphingolipids. Single molecule imaging with high resolution 
(millisecond scale) has made it possible to observe the spatiotem-
poral dynamics of molecular clustering on cell surfaces.40 It has 
become possible to observe processes of actual formation of 
molecular complexes on the cell surface.40 The results of these 
imaging experiments have been markedly changing the concept 
of GEM/rafts. Minimal units of nanoscale GEM/rafts might be 
dimer formation of glycosphingolipids with the same structure,41 
whereas GPI- anchored proteins should play central roles in the 
solid and microscale membrane domains.42 Analysis of interac-
tions between cancer- associated glycosphingolipids and inter-
acting molecules with high- resolution single molecule imaging 
would reveal new mechanisms for the generation of “cancer- 
associated glyco- signals”.43 One more novel technique that has 
supported single molecule imaging is that of chemical synthesis 
technology of fluorescence- labeled glycosphingolipids.44 A new 
method to label glycosphingolipids developed by Komura et al is 
based on the incorporation of fluorescent dye in the carbohy-
drate portion of glycosphingolipids by maintaining their primary 
natures. This point is markedly different from the fluorescent cer-
amide analogue that was widely used in the trafficking, transfer, 
intracellular localization, and metabolism of glycosphingolipids.45 
Modification of the ceramide moiety might generate confusing 
data, as lipid portions are essential for the intracellular traffick-
ing and localization of glycosphingolipids. The new method has 
F IGURE  6 Three phases of lipid raft formation. Lipid 
rafts in phase 1 are in a resting state forming a nanoscale 
assembly consisting of cholesterol, sphingomyelin, and 
glycosylphosphatidylinositol (GPI)- anchored proteins. The majority 
of glycosphingolipids are also present. Phase 2 rafts represent 
activated, clustered states forming a raft platform. Phase 3 means 
the raft phase with large cluster formation containing some trans- 
membrane molecules. The size of phase 3 rafts is large enough 
for them to be detected by current methods, ie, microscale rafts 
(modified from Lingwood et al39 with permission)
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enabled us to obtain reasonable results concerning the dynamics 
of glycosphingolipids.
For a long time, glycosphingolipids have been considered to be 
regulatory molecules, particularly in the nervous system, mainly be-
cause of their abundant expression in neuronal cells.46 However, it 
was reported that fine structures of glycosphingolipids are not es-
sential for the existence of bio- organisms, but they are pivotal reg-
ulators of various cells and organs based on the regulation of cell 
signals in GEM/rafts.47 What should be emphasized here is that the 
cluster formation of glycosphingolipids with homopolymer mode 
could be critical for recognition by ligand molecules. Recently, het-
eropolymers have also been reported to sometimes be essential for 
interactions with cis- and trans- acting ligands such as lectins.48-50 
These molecular clusters in GEM/rafts should affect the assembly/
dispersion of other membrane molecules in/from GEM/rafts,51 lead-
ing to the functional regulation of those membrane molecules.51,52,53 
Furthermore, molecular complex formation in a vertical direction 
through the cell membrane is also crucial for the determination of 
cell fates.
Now, glycosphingolipids are emerging as regulators of mem-
brane environments and cancer microenvironments, not just mark-
ers of cell differentiation and malignant transformation.
Based on novel findings on the functions and modes of action 
of cancer- associated glycosphingolipids, novel therapeutic trials 
have been carried out, or considered.54 For example, when a novel 
signaling pathway activated by cancer- associated glycosphingo-
lipids is found, key molecules in the pathway could be targets of 
therapy. In fact, p130Cas and paxillin, which are activated in GD3+ 
melanomas, were examined as possible target molecules for siRNA 
therapy.55 Membrane proteins that are identified as partners of 
cancer- associated glycolipids might be better targets for treatment. 
Downstream signal molecules of these partner membrane molecules 
could be more specific for cancer cells. Furthermore, identification of 
new epitopes formed by molecular complexes consisting of cancer- 
associated glycolipids and their partners might be expected as new 
targets. If particular molecules in glycosylation machineries are con-
sidered to be cancer- specific, and to play key roles, they could also 
be new targets of cancer therapy.
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